310 related articles for article (PubMed ID: 26818092)
1. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
[TBL] [Abstract][Full Text] [Related]
2. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
[TBL] [Abstract][Full Text] [Related]
3. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
[TBL] [Abstract][Full Text] [Related]
4. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
[TBL] [Abstract][Full Text] [Related]
5. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
6. A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma.
Crovella S; Moura RR; Cappellani S; Celsi F; Trevisan E; Schneider M; Brollo A; Nicastro EM; Vita F; Finotto L; Zabucchi G; Borelli V
J Toxicol Environ Health A; 2018; 81(5):98-105. PubMed ID: 29265930
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
[TBL] [Abstract][Full Text] [Related]
9. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
Betti M; Ferrante D; Padoan M; Guarrera S; Giordano M; Aspesi A; Mirabelli D; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Matullo G; Piccolini E; Magnani C; Dianzani I
Mutat Res; 2011 Mar; 708(1-2):11-20. PubMed ID: 21277872
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
Matullo G; Guarrera S; Betti M; Fiorito G; Ferrante D; Voglino F; Cadby G; Di Gaetano C; Rosa F; Russo A; Hirvonen A; Casalone E; Tunesi S; Padoan M; Giordano M; Aspesi A; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Piccolini E; Neri M; Musk AW; de Klerk NH; Hui J; Beilby J; James AL; Creaney J; Robinson BW; Mukherjee S; Palmer LJ; Mirabelli D; Ugolini D; Bonassi S; Magnani C; Dianzani I
PLoS One; 2013; 8(4):e61253. PubMed ID: 23626673
[TBL] [Abstract][Full Text] [Related]
12.
Cheng YY; Mok E; Tan S; Leygo C; McLaughlin C; George AM; Reid G
Dis Markers; 2017; 2017():2536187. PubMed ID: 29386699
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
[TBL] [Abstract][Full Text] [Related]
15. The role of single nucleotide polymorphisms related to iron homeostasis in mesothelioma susceptibility after asbestos exposure: a genetic study on autoptic samples.
Grignani P; Visonà SD; Fronda MV; Borrelli P; Monti MC; Bertoglio B; Conti A; Fattorini P; Previderè C
Front Public Health; 2023; 11():1236558. PubMed ID: 37942251
[TBL] [Abstract][Full Text] [Related]
16. Physician requests by patients with malignant pleural mesothelioma in Japan.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
[TBL] [Abstract][Full Text] [Related]
17. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
[TBL] [Abstract][Full Text] [Related]
20. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
Lin RT; Chang YY; Wang JD; Lee LJ
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]